Oct 29 2026 09:09 PM EST

Oct 29 2026

Biotech Momentum and Brazilian Finance Votes Shape Five‑Day Market Moves

Twist Bioscience (NASDAQ: TWST) rallied about 5.9% after reporting a 23% YoY revenue increase and raising its FY2026 outlook, while Banco Bradesco (NYSE: BBD) surged up to 19% on election‑driven sentiment, a new cash dividend and a R$10 bn capital raise. Sabesp (B3: SBSP3) jumped 17.8% after shareholders approved a R$70 bn infrastructure plan and a recent tariff increase. The divergent moves highlight sector‑specific growth drivers and macro‑policy tailwinds.

Twist posted Q3 FY2026 revenue of $118.4 million, up >23% YoY, with gross margin improving to 52.8% and adjusted EBITDA narrowing to –$11.3 million. Management lifted full‑year guidance to $456‑$457 million and reiterated a Q4 EBITDA breakeven target. Bradesco reported Q2 net income of R$7.1 bn (+16.2% YoY) and ROAE of 16.2%, while announcing a cash dividend of BRL 0.342 per share and a R$10 bn capital increase for digital and crypto‑custody projects. Sabesp’s Q1 adjusted EPS rose 29% to R$0.44, EBITDA grew 26% to R$3.8 bn (margin 63%), and the regulator approved a 6.5% tariff hike effective Jan 1 2026.

Biotech Momentum Drives Twist Surge

Twist’s growth aligns with expanding synthetic‑DNA demand in next‑generation sequencing and AI‑enabled drug discovery. The company’s silicon‑chip platform delivers base costs of $0.003‑$0.007, supporting a diversified client base of over 3,500 accounts. New “Express Genes” premium service and the Complex Genes offering (up to 7,000 bp) aim to capture higher‑margin opportunities. Analysts from TD Cowen, Leerink and Baird raised price targets into the $115‑$115 range, reflecting confidence in the upgraded revenue outlook. Risks noted include rising SG&A expenses, stock‑based compensation, a single‑supplier component exposure, and competition from larger incumbents and enzymatic synthesis technologies.

Brazilian Banking Gains from Election Sentiment and Dividend

The October 4 election runoff, featuring a right‑wing challenger, was interpreted as market‑friendly, prompting Bradesco shares to climb as much as 19% on October 5. The dividend announcement reinforced the bank’s attractive yield (TTM ≈ 6.7%). The approved R$10 bn capital increase, earmarked for the “Next” digital franchise, AI‑driven “Bridge” operating system and crypto‑custody services, signals a strategic shift toward higher‑margin technology revenue. Insider purchases of $0.9‑$1.5 million and an 18% drop in short interest further buoyed sentiment. Analysts upgraded the stock to “Buy” while trimming the price target to R$22.00, citing the earnings upgrade and margin expansion despite a modest rise in funding costs.

Sabesp’s Share Jump on Capital‑Plan Approval

Shareholders endorsed amended bylaws that grant the board flexibility to raise additional capital and accelerate a R$70 bn investment programme through 2029 (and R$260 bn to 2060). The vote triggered a 17.8% intraday rally, closing at $5.38 after opening at $6.23. Robust Q1 performance—revenue up 10.9% to R$6.021 bn and net income up 32% to R$1.5 bn—combined with a regulator‑approved 6.5% tariff increase, underpinning the outlook. The Inter‑American Development Bank’s US$1.35 bn B‑bond and US$200 million A‑loan provide financing capacity for the expanded asset base, now projected at R$87 bn for 2025. Analysts raised EPS forecasts to $0.51 for the next year and maintain a majority “Buy” rating, while noting risks from high SELIC‑driven borrowing costs and potential regulatory delays.

Common Themes: Macro Tailwinds and Capital Allocation

Both the biotech and Brazilian finance sectors benefited from macro‑level tailwinds. Twist’s revenue surge reflects broader growth in the synthetic‑biology market (estimated $48 bn in 2024) and the NGS industry’s 20% CAGR outlook, while Bradesco and Sabesp capitalised on Brazil’s high SELIC rate (13.75%‑14.25%) that supports net‑interest margins and provides attractive yields for infrastructure financing. In each case, companies leveraged strategic capital‑raising—Twist via its “Factory of the Future,” Bradesco through a digital‑focused R$10 bn increase, and Sabesp via a multi‑decade capital plan—to fund growth initiatives.

Outlook and Risks

Twist must contain SG&A growth (up 27% YoY) and manage stock‑based compensation to achieve the Q4 EBITDA breakeven target; any supply‑chain disruption could pressure its margins. Bradesco faces credit‑quality concerns, with Stage 2 loans rising and NPLs near 4.3%, while competition from fintechs like Nubank could erode fee income. Sabesp’s execution risk centers on timely capex deployment and the realization of tariff hikes; a repeat drought could force water‑rationing measures that dampen revenue. Collectively, the five‑day moves illustrate how investors reward clear earnings upgrades, strategic capital allocation, and favorable macro conditions, but remain vigilant to execution and sector‑specific headwinds.